ZA200602260B - A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug - Google Patents

A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug

Info

Publication number
ZA200602260B
ZA200602260B ZA200602260A ZA200602260A ZA200602260B ZA 200602260 B ZA200602260 B ZA 200602260B ZA 200602260 A ZA200602260 A ZA 200602260A ZA 200602260 A ZA200602260 A ZA 200602260A ZA 200602260 B ZA200602260 B ZA 200602260B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
receptor antagonist
inflammatory drug
nonsteroidal anti
nonsteroidal
Prior art date
Application number
ZA200602260A
Other languages
English (en)
Inventor
Boughton-Smith Nigel
Cruwys Simon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200602260B publication Critical patent/ZA200602260B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200602260A 2003-09-18 2006-03-17 A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug ZA200602260B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination

Publications (1)

Publication Number Publication Date
ZA200602260B true ZA200602260B (en) 2007-07-25

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200602260A ZA200602260B (en) 2003-09-18 2006-03-17 A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug

Country Status (20)

Country Link
US (1) US20070082930A1 (fr)
EP (1) EP1663224A1 (fr)
JP (1) JP2007505900A (fr)
KR (1) KR20060086942A (fr)
CN (1) CN1859911A (fr)
AR (1) AR045783A1 (fr)
AU (1) AU2004271886B2 (fr)
BR (1) BRPI0414558A (fr)
CA (1) CA2538416A1 (fr)
IL (1) IL173913A0 (fr)
IS (1) IS8396A (fr)
MX (1) MXPA06002722A (fr)
NO (1) NO20061662L (fr)
NZ (1) NZ545964A (fr)
RU (1) RU2338556C2 (fr)
SE (1) SE0302488D0 (fr)
TW (1) TW200526199A (fr)
UY (1) UY28517A1 (fr)
WO (1) WO2005025571A1 (fr)
ZA (1) ZA200602260B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
EP1644042A1 (fr) * 2003-05-29 2006-04-12 AstraZeneca AB Composition pharmaceutique comprenant un antagoniste au recepteur p2x7 et du metotrexate
WO2004105797A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007008157A1 (fr) * 2005-07-11 2007-01-18 Astrazeneca Ab Nouvelle combinaison 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007098086A2 (fr) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Dérivés d'hydroxypipéridine et leurs utilisations
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (fr) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinaisons formées de modulateurs au prolinamide du récepteur p2x7 et d'autres agents thérapeutiques
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
US8691556B2 (en) 2009-12-08 2014-04-08 Vanderbilt University Methods and compositions for vein harvest and autografting
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
WO2013082565A1 (fr) * 2011-12-02 2013-06-06 Michael Kaleko Thérapies pour des troubles de la cornée et de la conjonctive
CA2959601A1 (fr) 2014-09-10 2016-03-17 Novartis Ag Compositions de diclofenac sodique a usage topique

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
EP0952832B1 (fr) * 1996-05-20 2008-08-27 Darwin Discovery Limited Carboxamides de quinoline en tant qu'inhibiteurs de tnf et inhibiteurs de la photodiesterase-iv
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CN1147483C (zh) * 1999-04-09 2004-04-28 阿斯特拉曾尼卡有限公司 金刚烷衍生物
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US8058441B2 (en) * 2001-07-02 2011-11-15 N.V. Organon Tetrahydroquinoline derivatives
WO2003042190A1 (fr) * 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (fr) * 2003-05-29 2006-04-12 AstraZeneca AB Composition pharmaceutique comprenant un antagoniste au recepteur p2x7 et du metotrexate
WO2004105797A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
RU2338556C2 (ru) 2008-11-20
UY28517A1 (es) 2005-04-29
NO20061662L (no) 2006-04-11
NZ545964A (en) 2009-09-25
IL173913A0 (en) 2006-07-05
CN1859911A (zh) 2006-11-08
TW200526199A (en) 2005-08-16
CA2538416A1 (fr) 2005-03-24
JP2007505900A (ja) 2007-03-15
MXPA06002722A (es) 2006-06-06
BRPI0414558A (pt) 2006-11-07
WO2005025571A1 (fr) 2005-03-24
RU2006112423A (ru) 2007-11-10
US20070082930A1 (en) 2007-04-12
IS8396A (is) 2006-04-03
KR20060086942A (ko) 2006-08-01
AU2004271886A1 (en) 2005-03-24
AU2004271886B2 (en) 2008-03-20
AR045783A1 (es) 2005-11-16
SE0302488D0 (sv) 2003-09-18
EP1663224A1 (fr) 2006-06-07

Similar Documents

Publication Publication Date Title
ZA200602260B (en) A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
IL166286A0 (en) Multicomponent pharmaceutical dosage form
IL165383A0 (en) Pharmaceutical compositions with improved dissolution
DE602004017847D1 (de) Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
GB0413729D0 (en) A pharmaceutical composition and its use
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
EP1477403A4 (fr) Distributeur de medicament
IL169112A (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
PT1592426E (pt) 2-cianopirrolopirimidinas e seus usos farmacêuticos
ZA200701059B (en) Pharmaceutical dosage forms comprising a low-solubllity drug and a polymer
EP1898922A4 (fr) Medicament ou composes pharmaceutiques ameliores et preparation associee
IL174958A0 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IL169575A0 (en) Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
PL353613A1 (en) Application of oestrogen agonist/antagonist in production of a drug
DE60029340D1 (de) Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
IL161997A (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
IL161143A0 (en) A flash-melt pharmaceutical oral dosage composition
IS8188A (is) Lyfjablanda sem felur í sér P2X7 viðtakamótlyf ogæxlisdrepboða a
AU2003304236A1 (en) Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
DK1808446T3 (da) IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
AU2003267231A8 (en) Pharmaceutical compositions with improved dissolution
IL172087A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
AU2003257982A8 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage